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Aims Pluripotent stem cell-derived endothelial cell products possess therapeutic potential in ischaemic vascular disease.
However, the factors that drive endothelial differentiation from pluripotency and cellular specification are largely
unknown. The aims of this study were to use single-cell RNA sequencing (scRNA-seq) to map the transcriptional
landscape and cellular dynamics of directed differentiation of human embryonic stem cell-derived endothelial cells




A highly efficient directed 8-day differentiation protocol was used to generate a hESC-derived endothelial cell
product (hESC-ECP), in which 66% of cells co-expressed CD31 and CD144. We observed largely homogeneous
hESC and mesodermal populations at Days 0 and 4, respectively, followed by a rapid emergence of distinct endo-
thelial and mesenchymal populations. Pseudotime trajectory identified transcriptional signatures of endothelial com-
mitment and maturation during the differentiation process. Concordance in transcriptional signatures was verified
by scRNA-seq analysis using both a second hESC line RC11, and an alternative hESC-EC differentiation protocol.
In total, 105 727 cells were subjected to scRNA-seq analysis. Global transcriptional comparison revealed a tran-
scriptional architecture of hESC-EC that differs from freshly isolated and cultured human endothelial cells and from
organ-specific endothelial cells.
...................................................................................................................................................................................................
Conclusion A transcriptional bifurcation into endothelial and mesenchymal lineages was identified, as well as novel transcrip-
tional signatures underpinning commitment and maturation. The transcriptional architecture of hESC-ECP was dis-
tinct from mature and foetal human EC.
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Cardiovascular disease remains the most common cause of mortality
globally despite improved pharmacological and interventional
options.1 For example, current interventions for critical limb ischae-
mia are unsuccessful, with 43% of patients requiring limb amputation
within 5 years.2 Similarly, for myocardial infarction 25% of patients
still progress to heart failure owing to the overburdening of the
remaining viable myocardium.3
Consequently, using stem-cell therapies to promote vascular re-
generation is a promising strategy for treating ischaemic disease.
However, despite studies yielding positive results in small animal
models of ischaemia, the efficacy of using such cells in human trials
has been disappointing, providing limited benefit.4
While many protocols have tested autologous cells, a number of
studies have recently assessed the use of pluripotent cells in relevant
animal models5 and more recently clinically.6 As such, derivation and
production of therapeutic cells from pluripotent sources are
required using an efficient and GMP compliant protocol.
Transplantation of pluripotent stem cell-derived endothelial cells
(PSC-EC) has been demonstrated to promote therapeutic angiogen-
esis in a range of small animal models of ischaemia.7,8 However, differ-
entiation protocols are limited by their low efficiency resulting in
substantial and uncharacterized heterogeneity within the final cell
population.9
We recently reported a rapid and efficient protocol7 for produc-
tion of a regenerative human embryonic stem cell-derived endothe-
lial cell product (hESC-ECP), adapted from the protocol of Patsch et
al.10 The protocol consistently yields CD31þ/CD144þ cells com-
prising 60% of the population, with the remaining cells expressing
pericyte and mesenchymal markers and, crucially, exhibiting no re-
sidual pluripotency.7 When injected into ischaemic muscle, a robust
pro-angiogenic response was evident across a range of mouse mod-
els.7 Despite the expression of mature endothelial cell (EC) markers
by cells from the hESC-ECP, it is likely that these cells remain tran-
scriptionally immature and are non-specified further into arterial,
venous, or lymphatic lineages.7
Comprehensive characterization of the transcriptional dynamics
throughout differentiation is a crucial step towards understanding the
key molecular regulators and mechanisms governing commitment
and maturation of EC. Additionally, defining the temporal changes in
pluripotent and angiogenic-related genes may provide insight into the
safety and functional efficacy of these cells. Recent studies of cardiac
and liver differentiation have demonstrated that longitudinal applica-
tion of single-cell RNA sequencing (scRNA-seq) permits tracking of
transcriptional changes throughout differentiation at single-cell
resolution.11,12
A recent study used scRNA-seq to attempt to understand the
directed differentiation of induced pluripotent stem cells-derived EC,
yet the final cell population was highly heterogeneous, consisting of
fewer than 10% EC and co-populated by cardiac-like and hepatic-like
cells.9 Development of droplet-based scRNA-seq platforms has
enabled the sequencing of thousands of cells in parallel, and the rigor-
ous unbiased modelling of cellular heterogeneity.13 Consequently,
application of these platforms for characterizing human embryonic
stem cell-derived endothelial cells (hESC-EC) has clear advantages
over previous studies that surveyed fewer than 100 cells.14
In this study, we sought to use scRNA-seq to dissect the cellular
heterogeneity and transcriptional dynamics of hESC-EC differenti-
ation and maturation, utilizing alternative hESC lines and two different
differentiation protocols. Maturity and specification of hESC-EC fol-
lowing their initial commitment were assessed throughout the pro-
cess by comparison to foetal and adult endothelial cells from various
sources. We also aim to evaluate the clinical suitability of our hESC-
ECP by comparison to the products of an alternative differentiation.
Methods
Human embryonic stem cell-derived endo-
thelial cell differentiation
H9 and RC11 hESC lines were differentiated to hESC-ECP using our pre-
viously reported protocol.7 Human ESC lines were used in accordance
with the UK Stem Cell Bank Steering Committee guidelines (Project
Approvals SCS11-51 and SCSC17-26). Briefly, hESC were plated on a
fibronectin matrix at Day 0 (d0). At d1, lateral mesoderm was induced
with GSK3 inhibitor (CHIR99021) (7lM) and BMP4 (25 ng/mL) added to
N2B27/Neurobasal/DMEM:F12 media. This was followed by endothelial
cell induction at d4 with Forskolin (2lM) and vascular endothelial growth
factor (VEGF) (200 ng/mL) in StemPro34 media. In the final step, cells
were replated and cultured until d8 or d12 with human AB serum (1%)
and VEGF (50 ng/mL) in EGM-2 media. Cells were taken for scRNA-seq
at d0 (H9 only), d4, d6, d8, and d12 (H9 only).
In the alternative differentiation protocol H9 hESC were differentiated
to hESC-EC as described by Zhang et al.15 In summary, hESC were plated
as single cells on a vitronectin matrix and cultured in E8 media supple-
mented with BMP4 (5 ng/mL), Activin A (25 ng/mL), and
CHIR99021(1lM). From d2 to d6, media was changed to E5 media sup-
plemented with FGF (100 ng/mL), VEGF (50 ng/mL), SB431542 (10lM),
RESV (resveratrol) (5lM), and L690 (10lM). Cells were harvested for
scRNA-seq at d2, d4, and d6.
Translational perspective
Ischaemic conditions contribute substantially to global mortality and morbidity. Human embryonic stem cell-derived endothelial cells (hESC-
EC) offer a promising strategy to promote therapeutic angiogenesis in tissue ischaemia. Our good manufacturing practice (GMP) compliant
protocol for the generation of hESC-EC promotes therapeutic angiogenesis in vivo. However, knowledge of the transcriptional dynamics of
hESC-EC differentiation is currently limited. Here, we apply single-cell RNA sequencing to two hESC differentiation protocols. We character-
ize the transcriptional dynamics of hESC-EC, important for informing how to drive controlled angiogenesis, endothelial cell maturation, and
specification. We also evaluate the cellular heterogeneity at each stage using a hESC-EC differentiation protocol that is relevant to clinical cell
therapy.
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Single-cell RNA sequencing library
construction
Following determination of their number and viability, dissociated cells
were loaded into the 10X Chromium Controller. Library construction
was performed using the Single Cell 3’ Reagent Kit. To summarize, in re-
action vesicles (gel beads in emulsion, GEMs), cells were lysed and bar-
coded oligonucleotides reverse transcribed before clean-up and cDNA
amplification. The Chromium Single-Cell 3’ Library Kit was then used to
generate indexed sequencing libraries. Library sequencing was performed
using either Illumina HiSeq 4000 or Illumina NovaSeq 6000 platforms.
Recovery rates ranged from between 3778 and 10 053 cells, with the
number of reads per cell ranging between 35 630 and 119 015
(Supplementary material online, Table S1).
Single-cell RNA sequencing data analysis
Raw reads were processed using the 10X CellRanger pipeline to align
these to the reference transcriptome (GRCh38) and to generate gene-
cell count matrices. Initial QC and clustering was performed with the aid
of Seurat version 2.2.1.16 In an attempt to remove dead or falsely identi-
fied cells, as well as doublets, cells either expressing fewer than 250 genes,
having a UMI count greater than 10 000, or having greater than 15% of
reads mapping to mitochondrial genes were excluded from further ana-
lysis. Following data normalization and scaling to remove unwanted sour-
ces of variation16 principal component analysis (PCA) was conducted
using genes with highly variable expression. Seurat graph-based cluster-
ing16 was then applied followed by tSNE allowing the visualization of iden-
tified clusters in tSNE plots. Differential gene expression (DGE) analysis
was then used to identify significantly differentially expressed genes within
each cluster using the Wilcoxon test for significance (adjusted P value
<0.05) and a loge(FC) greater than 0.25. Signature scores were calculated
by taking the mean of the scaled and centred expression values across
multiple signature genes (Supplementary material online, Methods).
Pseudotime trajectories of differentiation were generated using the
Monocle R Package v.2.6.4.17 Pseudotime analysis proceeds on the basis
that cells undergo biological processes in an asynchronous manner, and
thus that cells can be ordered along a calculated trajectory to infer the
transcriptional changes throughout the process. Genes that were most
differentially expressed (q< 10-40) in identified clusters were used to as-
sign pseudotime values to individual cells. Differentially expressed genes
across pseudotime were identified using the differentialGeneTest com-
mand in Monocle.17 RNA velocity of individual cells was calculated using
the Velocyto R package (V0.6.0).18 RNA velocity analysis determined the
fraction of spliced-to-unspliced reads to predict the future transcriptional
state of individual cells. All sequencing data have been deposited in the
Gene Expression Omnibus (GEO; GSE131736).
All further experimental and analysis details are included in the
Supplementary material online, Methods.
Results
Longitudinal Single-cell RNA
sequencing analysis reveals the
emergence of committed endothelial
and mesenchymal lineages from a
homogeneous mesodermal population
Human embryonic stem cells (H9) underwent an 8-day differenti-
ation protocol7 via a mesodermal stage to form a hESC-EC product
(Figure 1A). At Day 8, two-thirds (65.7%) of the cells were CD31þ/
CD144þ with fewer than 0.05% co-expressing pluripotent markers
SSEA4/TRA-181 as shown by flow cytometry (Figure 1B). Single-cell
transcriptomics data were obtained from 21 369 cells harvested at
four time points across the differentiation protocol using droplet-
based microfluidic technology (Figure 1A).
Cellular heterogeneity was characterized at each time point using
PCA. The starting hESC population (d0) was largely homogeneous:
99.7% and 95.9% of cells expressed pluripotent markers POU5F1
(OCT4) and SOX2, respectively (Supplementary material online,
Figure S1A).
At Day 4 (d4), 97.4% of cells expressed lateral mesoderm marker
HAND1 (Figure 1C). The paucity of cells expressing early and late
endothelial markers [KDR (5.4%) and PECAM1 (0.16%), respectively]
demonstrated that this population was not pre-determined to an
endothelial lineage (Figure 1C). In cluster d4-B, reduced expression of
MIXL1 (Figure 1C) coupled to a higher expression of bone marrow
stromal cell marker BST2 (Supplementary material online, Figure S1B),
suggested pre-disposition to a mesenchymal fate.19
In contrast, cells at Day 6 (d6) and Day 8 (d8) were dichotomized
into two divergent populations (Figure 1C). The first was character-
ized by expression of endothelial markers (KDR and PECAM1), and
the second by mesenchymal markers such as ACTA2 (Figure 1C).
Residual heterogeneity within both populations at either d6 or d8
reflects cell cycle variation, indicated by MKI67 expression (Figure
1C). Cluster d8-F (3.2%) likely represented a doublet cluster owing
to the expression of both mesenchymal and endothelial markers,
whilst lacking unique markers (Supplementary material online, Figure
S1D).
By d8, fewer than 0.5% of cells expressed either POU5F1 or SOX2
with no cells co-expressing both markers (Supplementary material
online, Figure S2), confirming the absence of residual pluripotency.
Mesodermal markers MIXL1 and HAND1 were expressed in 12% and
14% of d8 cells, respectively (Supplementary material online, Figure
S2) confirming a non-mesodermal population.
At Day 8, hESC-EC and mesenchymal populations expressed
angiogenesis associated genes such as TGFB1, HIF1A, and FLT1 sug-
gesting contribution to the pro-angiogenic effect (Supplementary ma-
terial online, Figure S3). Other pro-angiogenic markers, such as TIE1
and ANGPT2, were highly expressed in the endothelial lineage whilst
TGFB2 and FGF1 were primarily expressed within mesenchymal
clusters.
To investigate phenotypical changes beyond d8, we repeated the
differentiation and processed an additional 13 657 H9 cells at d8 and
d12. Separation of endothelial and mesenchymal populations at Day
8 was replicated in both rounds of differentiation as well as in a previ-
ous replicate (n= 3) (Supplementary material online, Figure S4).
Distinct endothelial and mesenchymal populations were still evident
at Day 12 (Figure 1D). The proportion of endothelial cells in cycle
decreased from 49.6% at d8 to 23.1% at d12 (D12-B). No cluster
representing cycling cells was identified in the d12 mesenchymal
population.
Genes that were differentially expressed in cluster D8-E (such as
ENPP2, TIE1, and CLDN5) showed elevated expression in hESC-EC at
d12 in comparison to at d8 (Figure 1E).20–22 This is consistent with
the observed increase in cell confluency (Supplementary material on-
line, Figure S5). Furthermore, Gene Ontology (GO) term enrichment
analysis revealed extracellular matrix organization to be a significantly
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Figure 1 Single-cell RNA sequencing analysis of human embryonic stem cells-derived endothelial cell product differentiation at individual time
points. (A) Schematic of human embryonic stem cells-derived endothelial cell product differentiation and single-cell RNA sequencing pipeline. (B)
Representative flow cytometric analysis of cells taken at Day 8 (human embryonic stem cells-derived endothelial cell product). Cells stained for
endothelial (CD31 and CD144) (right panels), pluripotent markers (TRA-181 and SSEA-4) (left panels), and their corresponding isotype controls.
(C) tSNE plots, constructed separately, using data from cells sampled at Days 4, 6, and 8 for single-cell RNA sequencing. Feature plots (right) show
key marker gene expression for each population. (D) tSNE plot constructed from d12 data from a separate round of H9 differentiation. (E) Violin
plots showing expression (ln(UMIþ 1)) of angiogenic and cell contact related genes in d8 and d12 human embryonic stem cell-derived endothelial
cells. (F) Gene Ontology term analysis conducted using genes significantly differentially expressed within d12 human embryonic stem cell-derived
endothelial cells in comparison to d8 human embryonic stem cell-derived endothelial cells.
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enriched term (Figure 1F). At each time point, hESC-ECs predomin-
antly expressed arterial markers as opposed to venous or lymphatic
ECs (Supplementary material online, Figure S6).
Longitudinal single-cell RNA sequencing
analysis reveals rapid endothelial
differentiation and subsequent
maturation following a bifurcation point
In order to characterize the transcriptional changes throughout dif-
ferentiation, data from all time points were combined and normalized
(see Methods section) prior to conducting PCA and data visualization
(tSNE). Cells from d0 and d4 each formed a separate cluster, where-
as d6 and d8 cells separate into endothelial or mesenchymal popula-
tions (Figure 2A). To trace transcriptional dynamics associated with
each identified cell type, expression values of pluripotent, mesoder-
mal, mesenchymal, and endothelial markers were used to calculate a
score for each of the four signatures for each individual cell (see
Supplementary material online, Methods). As expected, 100% of d0
cells were positive for the pluripotent signature (Figure 2B and C),
whereas virtually no d4 cells were positive for this signature.
Similarly, d4 cells were mainly positive for the mesodermal signature
(Figure 2B and C) with enriched expression of APLNR (Supplementary
material online, Figure S7). Increased endothelial and mesenchymal
signature scores for d6 and d8 within their respective populations
suggested that both cell types have matured further following initial
specification (Figure 2B and C).
The concept of RNA velocity can be used to predict future tran-
scriptional states, taking advantage of changes in read fractions in
exonic vs. intronic sequence.18 RNA velocities in Figure 2E are repre-
sented by the size and direction of arrows. The paucity of vectors
with large magnitude and coherent direction associated with d0 and
d4 cells is indicative of their equilibrium state (Figure 2E). Vectors
associated with either endothelial or mesenchymal cell clusters indi-
cated the direction of cell type maturity. The larger vectors for the
d8 mesenchymal cell cluster, compared with the d8 endothelial clus-
ter, is consistent with the latter reaching a steadier equilibrium state
following initial maturation (Figure 2E).
Early (d6) and late (d8) EC and mesenchymal populations exhibit
high transcriptional similarity (Figure 2D). Nevertheless, higher ex-
pression of transcription factor (TF) SNAI2 was observed in the early
(d6) mesenchymal population in comparison to later mesenchymal
population (d8) (Supplementary material online, Figure S8). Similarly,
higher expression of genes such as SOX7 and GJA4 at d6 defines these
as markers of early endothelial specification (Supplementary material
online, Figure S9A and B). Conversely, higher expression of GNG11,
ESM1, and ANGPT2 at d8 defines these as later markers of endothelial
maturation (Supplementary material online, Figure S9A and B). RT-
qPCR analysis of several marker genes utilizing RNA from CD144þ
and CD144- populations at d6 and d8 demonstrated high concord-
ance with scRNA-seq findings (Supplementary material online,
Figure S10). A complete list of significantly differentially expressed
genes for all compared datasets is provided in Supplementary mater-
ial online, File S1.
To ensure findings were not limited to H9 cells, an alternative
hESC line, the RC11 line, was used to reproduce findings. Cells were
sampled for scRNA-seq at Days 4, 6, and 8 (total of 21 972 cells) and
the identical analysis applied. Strikingly, we identified equivalent
mesodermal, mesenchymal, and endothelial populations in both
RC11- and H9-derived cells (Figure 2F). A small additional cluster was
identified defined by differential expression epithelial markers includ-
ing EPCAM, CDH1, and RAB25 (Supplementary material online, Figure
S11). This likely reflects an epithelial-to-mesenchymal transition dur-
ing mesoderm formation.23
Pseudotime analysis is a complementary approach used to deter-
mine the path and progress of individual cells undergoing differenti-
ation.17 The resultant trajectory for H9 hESC-ECP differentiation
(Figure 3A) indicated a bifurcation point giving rise to distinct endothe-
lial and mesenchymal branches, consistent with the divergence repre-
sented in Figure 2A. The majority of d4 cells had pseudotime values
close to zero, implying they had yet to commence endothelial or
mesenchymal differentiation (Supplementary material online, Figure
S12). Pseudotime analysis using RC11 cells reproduced an essentially
identical bifurcation point as using H9 (Figure 3B). Increasing expres-
sion of known endothelial markers (Figure 3C) and TF (Figure 3D)
defined the endothelial branch. Similarly, up-regulation of mesenchy-
mal markers and TF (Figure 3C and D) identified the mesenchymal
branch (Figure 3A). Expression of the same markers and TF during the
RC11 differentiation traced highly similar pseudotime trajectories
(Figure 3C and D).
Single-cell RNA sequencing analysis of an
alternative human embryonic stem cell-
derived endothelial cell differentiation
protocol reveals substantial
heterogeneity
A comparable longitudinal scRNA-seq data set was acquired using an
alternative hESC-EC differentiation protocol, namely the five-factor
protocol described by Zhang et al.15 This allowed us to compare its
cellular heterogeneity and transcriptional dynamics with those from
our 8-day differentiation protocol. Using the Zhang et al. 6-day proto-
col, differentiated H9 cells yielded 51.8% CD31þ/CD144þ cells by
Day 6 (Supplementary material online, Figure S13). Cells were
sampled for scRNA-seq at a mesodermal stage (d2) and two endo-
thelial stages (d4 and d6). We sequenced the transcriptomes of
27 225 cells. Unsupervised clustering revealed the presence of 12 in-
dividual clusters (Figure 4A and B).
Within the d2 population, a large (22%) epithelial cluster was iden-
tified, characterized by expression of markers including EPCAM,
RAB25, and CLDN4 (Figure 4C and D). The remaining d2 cells were
characterized by expression of mesodermal markers HAND1 and
BMP4. Interestingly, d2 mesoderm was also positive for mesendo-
derm markers such as GSC and EOMES (Figure 4C and D). Expression
of a pluripotent marker, NANOG, was predominantly localized to the
epithelial cluster (Supplementary material online, Figure S14A).
By d4, 37% of cells localized to a distinct endothelial population
defined by expression of classical endothelial markers (Figure 4A–D).
The two-remaining major d4 clusters were defined by expression of
mesodermal markers (Figure 4A–D). In contrast to d2, d4 mesoderm
was predominantly negative for expression of mesendoderm markers
(Figure 4D). The 18.5% reduction of EOMESþ cells in cluster ‘meso-
derm 2’, in comparison to cluster ‘mesoderm 1’ likely identifies this as
the later of the two d4 mesoderm populations. Interestingly, a subset
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Figure 2 Single-cell RNA sequencing analysis across all time points mapping the transcriptional changes and predicted future direction of cells
undergoing human embryonic stem cells-derived endothelial cell product differentiation. (A) tSNE plot constructed using data from 21 369 cells taken
at Day 0, 4, 6, and 8 during H9 to human embryonic stem cells-derived endothelial cell product differentiation. Cluster identity determined by the ex-
pression of known pluripotent (SOX2), mesodermal (HAND1), mesenchymal (ACTA2), and endothelial markers (PECAM1). (B) Cell signature scores
shown on tSNE plot from A. (C) Cell signature scores within identified clusters from A. (D) Principal component analysis plot containing cells taken at
the four time points during H9 differentiation. Feature plots show key marker gene expression. (E) RNA velocities visualized on the principal compo-
nent analysis plot from D. (F) tSNE plot using data from d4, d6, and d8 during differentiation of RC11.
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Figure 3 Pseudotime trajectories of human embryonic stem cells-derived endothelial cell product differentiation. Pseudotime trajectories contain-
ing cells from d4, d6, and d8 during (A) H9 differentiation and (B) RC11 differentiation. Arrows show direction of pseudotime across trajectories.
Expression of known endothelial and mesenchymal (C) markers and (D) transcription factors in their respective branches for each of the two starting
ES cells (H9 and RC11).
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Figure 4 Longitudinal single-cell RNA sequencing analysis of an alternative human embryonic stem cell-derived endothelial cells differentiation
protocol. (A) tSNE plot showing data of human embryonic stem cell-derived endothelial cells differentiation using an alternative protocol. Cells taken
for single-cell RNA sequencing at d2, d4, and d6. (B) tSNE plot of alternative differentiation protocol, categorizing cells according to their original
data set. (C) Signature scores shown on tSNE plot from A. (D) Key marker gene expression used to characterize identified clusters. (E) Pseudotime
trajectory containing cells from d4 clusters of the alternative differentiation protocol.
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of cluster ‘mesoderm 2’ expressed both CD34 and KDR but not
PDGFRA suggesting a more specialized mesoderm with restricted spe-
cification to a hematoendothelial lineage24 (Supplementary material
online, Figure S14B). We annotated a small cluster of d4 cells that dif-
ferentially express endoderm markers, including FOXA2 and CLDN6 as
well as pluripotent marker POU5F1, as an early endoderm cluster with
residual pluripotency (Supplementary material online, Figure S14C).
At d6, a comparable HAND1þ mesoderm population was present
(Figure 4A–D). The large d6 endothelial cluster accounted for 43% of
d6 cells (Figure 4A–D). About 10.3% of d6 cells localized to a small
cluster exclusively expressing various known haemogenic markers
including SPN1, SPI1, and RUNX125 (Figure 4C and D). Furthermore, a
small d6 cluster (10.7% of d6 cells) was annotated as being a nephro-
genic population, defined by expression of PAX2, PAX8, and CRYM26
(Figure 4C and D).
We next used pseudotime analysis choosing cells at d4 over d6 so
as to compare early vs. late mesodermal populations. As expected,
the resultant trajectory (Figure 4E) revealed cells from the ‘mesoderm
1’ cluster preceding those from ‘mesoderm 2’. Unexpectantly, the bi-
furcation point giving rise to the endodermal population appeared to
emerge from the later, ‘mesoderm 2’ population. Endothelial and
mesodermal cells populated the start of the endothelial branch, thus
suggesting that endothelial commitment from mesoderm was still in




We sought to characterize the expression of transcription factors
over these trajectories. Using a comprehensive list of over 1600 likely
human TF27 we identified 144 that were significantly differentially
expressed over pseudotime in both RC11 and H9 differentiations. Of
these, several are known to be implicated in endothelial differenti-
ation (ERG, ETS1, SOX7,and ELF128) and these all resided within
Cluster 5 (containing 37 genes) of genes differentially expressed
across pseudotime (Figure 5A).
The expression profile of the 37 Cluster 5 TF (Figure 5A) was then
visualized along the endothelial branch of the trajectory from the
five-factor protocol (Figure 5B). Expression dynamics for the majority
of TF showed substantial resemblance to those observed in the five-
factor protocol (Figure 5C; Supplementary material online, Figure
S15). In addition, several TF with no clear reported link to endothelial
differentiation also followed a similar expression profile, and showed
remarkable concordance across cells and protocols (Figure 5C).
Human embryonic stem cell-derived
endothelial cells remain transcriptionally
distinct from mature and adult endothe-
lial cells despite undergoing additional
maturation following endothelial
commitment
We then sought to evaluate the maturity of hESC-EC produced by
comparison of scRNA-seq data of foetal endothelial cells and mature
endothelial cells with that from H9-derived cells. First, we combined
hESC-EC data from d6, d8, and d12 datasets with data obtained from
mature primary cultured ECs from each of the arterial, lymphatic, or
venous vascular beds. Principal component analysis revealed that
hESC-EC at d6, d8, and d12 cluster separately from mature EC
(Figure 6A). Interestingly, d12 hESC-EC clustered separately from
their d6 and d8 counterparts, but not visibly closer to any given ma-
ture EC. Large proportions of genes were expressed within hESC-
EC but not in mature EC (d8: 7.2%; d12: 7.3%; Figure 6B). Differential
gene expression analysis between d8 and d12 hESC-EC revealed
increasing expression levels of several ECM related genes, such as
COL4A1 and FN1 (Supplementary material online, Figure S16A).
Furthermore, between d8 and d12 hESC-EC an increase in endothe-
lial signature score was observed, suggesting of further maturation
beyond d8 (Supplementary material online, Figure S16B).
We then collected all publicly available 10X Chromium scRNA-
seq data sets including endothelial cell data from freshly isolated
human organs (Supplementary material online, Table S3). Differential
gene expression analysis of combined endothelial clusters (Figure 6C)
revealed key transcriptional markers for each organ-specific endothe-
lial phenotype (Supplementary material online, File S2). Visualization
of signature scores across all clusters demonstrated their high specifi-
city to their corresponding cluster (Figure 6D). Neither the d8 nor
d12 hESC-EC cluster was positive for any organ-specific signature
score, thus indicating their likely unspecified nature. Furthermore,
correlations between transcriptomes of endothelial cell types were
higher among the d6, d8, and d12 cells, than these cells were to foetal
(kidney) and mature endothelial cells (Figure 6E).
Discussion
In the present study, we performed the first longitudinal droplet-
based scRNA-seq analysis of our highly efficient hESC-EC differenti-
ation protocol.7 In two different hESC lines, endothelial differenti-
ation from a homogeneous lateral mesoderm population resulted in
a bifurcation leading to the emergence of non-specified endothelial
and mesenchymal populations. Each population was capable of
undergoing further maturation. We performed comparable scRNA-
seq analysis of an alternative hESC-EC differentiation protocol,
revealing substantially more heterogeneity during differentiation,
including the emergence of multiple non-endothelial populations by
the protocol endpoint. Pseudotime analysis comparing different
protocols and starting hESC lines uncovered robust transcriptional
signatures of endothelial differentiation. Finally, we compared the
hESC-EC transcriptional identity to those of primary cultured endo-
thelial cells and freshly isolated foetal and adult endothelial cells.
Despite hESC-EC appearing to undergo additional maturation fol-
lowing their initial commitment, they remained transcriptionally
distinct from foetal and mature endothelial cell types, with no indica-
tion of commitment to an organ-specific endothelial phenotype.
In contrast to earlier time points, at d6 we observed the emer-
gence of two distinct populations expressing either mesenchymal or
endothelial markers, a dichotomy that was confirmed by pseudotime
trajectory analysis. Recent studies have reported the existence of a
common mesenchyme and endothelial precursor, termed the mes-
enchymoangioblast (MB) derived from APLNRþ/KDRþ/PDGFRAþ
mesoderm.29 MB-derived mesenchymal cells were demonstrated to
emerge from an endothelial origin by endothelial-to-mesenchymal
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Figure 5 Pseudotime analysis of transcription factor expression during human embryonic stem cell-derived endothelial cells differentiation. (A)
Differential gene expression variance over pseudotime of H9 differentiation within pseudotime trajectory branches. Genes used are TF that are dif-
ferentially expressed in both H9 and RC11-derived trajectories. (B) Gene expression variance of TF taken from Cluster 5 of heatmap from A in the
endothelial branch of the trajectory from the five-factor protocol. (C) Spline plots showing the expression of novel TF from B across pseudotime in
RC11 and H9 human embryonic stem cell-derived endothelial cells differentiation using the original protocol, as well as for the five-factor protocol.
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Figure 6 Transcriptomic comparison of human embryonic stem cell-derived endothelial cells to mature endothelial cells. (A) Three-dimensional
principal component analysis plot of human embryonic stem cell-derived endothelial cells from d6, d8, and d12 datasets alongside mature endothelial
cell: human dermal lymphatic endothelial cells, human umbilical vein endothelial cells, and human pulmonary artery endothelial cells. (B) Venn dia-
grams of number of genes expressed in d6, d8, and d12 human embryonic stem cell-derived endothelial cells and the overlap of these genes with
each type of mature endothelial endothelial cell. Percentage of uniquely expressed human embryonic stem cell-derived endothelial cell genes shown
in red. (C) tSNE plot showing clustering of endothelial cell extracted from 10X datasets of human organs. (D) Signature scores for each endothelial
cell type shown in C. (E) Heatmap with hierarchical clustering comparing transcriptional status of each cell type by Spearman’s rank correlation
coefficient.
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transition (EndMT) in the absence of VEGF.30 However, other mes-
enchymal progenitors, called mesopheres, were found to develop in
the presence of VEGF and have shared phenotypic and transcrip-
tomic properties with MBs.31 The observed expression of the
EndMT-associated TF SNAI2 in the early mesenchymal population
may suggest induction of EndMT in the presence of VEGF.32
However, here, although the Day 4 mesodermal population select-
ively expressed APLNR, it was found not to express KDR or PDGFRA,
thus suggesting that mesenchymal and endothelial commitment is
more likely to occur independently from a common mesoderm
progenitor.24
In contrast to our own 8-day differentiation protocol,7 analysis of
the alternative, five-factor differentiation protocol15 revealed consid-
erably more heterogeneity, with an early mesendoderm population
identified by primitive streak markers and residual pluripotency (Take
home figure). Interestingly, the model proposed by Evseenko et al.24
shows early mesoderm can then undergo further specification to
KDRþ/CD34þ/PDGFRA- mesoderm which has limited specification
potential, forming only hematoendothelial lineages. This model may
explain the unexpected haemogenic endothelial cluster in the d6
population. The transcriptional signatures identified around the hae-
mogenic endothelial cluster demonstrated high concordance with
scRNA-seq analysis of an iPSC model of endothelial-to-hematopoi-
etic transition (EHT).25
We also identified expression patterns of several known and novel
TFs in all three hESC-EC pseudotime trajectories. For example, the
expression profile of BCL6B, which encodes a transcription factor
shown to be expressed within the endothelium of the developing
mouse kidney,33 showed remarkable similarity across all trajectories.
This suggests a potential role in endothelial differentiation and/or
maturation, making this a strong candidate for further experimental
validation. Additional cues such as shear stress are likely to be
required to drive EC maturation.34 Our initial attempts to subject d8
hESC-EC to shear stress resulted in detachment of cells (data not
shown), possibly due to cells not being at a sufficient level of matur-
ation to lay down the extracellular matrix necessary for effective
adhesion.
In addition, recent cell tracking studies revealed that the majority
of cells are lost soon after transplantation suggesting a paracrine de-
pendence in vivo.7,35 Crucially with scRNA-seq analysis, several angio-
genic factors such as FLT1 and HIF1A, were highly expressed across
both endothelial and mesenchymal populations in our d8 hESC-ECP.
Furthermore, the non-teratogenic nature of the hESC-ECP was fur-
ther demonstrated by the complete absence of cells co-expressing
SOX2 and POU5F1.
In conclusion, we have used a droplet-based scRNA-seq platform
to map the transcriptional changes throughout the differentiation of
hESCs to pluripotent stem cell-derived EC across different cell lines
and differentiation protocols. This provides novel insight into early
endothelial commitment and maturation and will aid in the refine-
ment of protocols that drive endothelial specification in a lineage or
organ-specific nature. We also provide essential evidence of the tran-
scriptional state and heterogeneity by Day 8 of our protocol, and we
are developing a first-in-man cell therapy approach using Day 8 differ-
entiated cells.
Supplementary material
Supplementary material is available at European Heart Journal online.
Take home figure Proposed model for the differentiation of the embryonic stem cells-derived endothelial cells via two differentiation meth-
ods. Human embryonic stem cells undergo highly efficient differentiation using the human embryonic stem cells-derived endothelial cell product dif-
ferentiation method, forming a homogeneous lateral mesoderm population. Following endothelial induction, a bifurcation point exists, giving rise to
early endothelial and mesenchymal populations. Conversely, in the five-factor protocol, human embryonic stem cells undergo differentiation to an
earlier mesendoderm population. Subsequent endothelial induction drives the mesendoderm to give rise to multiple unwanted cell types including
nephron progenitors and haemogenic endothelium. Despite clear differences in cellular heterogeneity, transcriptional dynamics of human embryonic
stem cells-derived endothelial cell differentiation has substantial commonalities between differentiation methods.
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